Company intelligence / Profile preview

NeuroPharm, Inc.

Vancouver, British Columbia, Canadaneuraxpharm.com ↗

Ownership: Private
Development stage: Preclinical

Overview

As a subsidiary of Mydecine Innovations Group since mid–2020, NeuroPharm is developing proprietary pharmaceutical and natural health products focused on mental wellness in vulnerable populations. Their main focus is on evidence-based psilocybin therapies for conditions like PTSD and depression in veterans. The company has engaged with FreeMind Group to secure non-dilutive funding for its programs.

Therapeutic areas: PsychiatryNeurology
Modalities: Psilocybin-based therapiesPharmaceutical and natural health products targeting mental wellness
Industry: Biotech

Drug pipeline

1 asset

mdma + psilocybin

Pre-clinical

Indications: PTSD

Partnerships

FreeMind Group LLC (funding strategy)strategic partners not named but include organizations serving veterans/emergency personnel

Beyond the preview

Go deeper on NeuroPharm, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroPharm, Inc..

Explore the full profile